The abstract is read at the publisher; the summary is JClub's.
Psilocybin is supported by clinical trials as a transitional treatment for cluster headache and migraine, with efficacy and safety reported in the limited evidence base.
- Why it matters: Headache disorders are common and treatment varies by disorder and individual needs, while renewed interest in psychedelics is driven by patient advocacy and emerging trial data.
- What they did: The Perspective reviews psychedelic drugs in headache medicine, highlighting historical roles and summarizing clinical trial evidence for psilocybin in cluster headache and migraine, alongside ongoing studies of other compounds.
- The result: The current findings suggest psilocybin may be effective and safe for transitional use in these headache disorders, informing future research while addressing safety, logistical, and legal constraints.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.